Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat

Abstract

Of the more than one million global cases of breast cancer diagnosed each year, approximately fifteen percent are characterized as triple-negative, lacking the estrogen, progesterone, and Her2/neu receptors. Lack of effective therapies, younger age at onset, and early metastatic spread have contributed to the poor prognoses and outcomes associated with… (More)
DOI: 10.1186/bcr3192

Topics

8 Figures and Tables

Cite this paper

@inproceedings{Tate2012TargetingTB, title={Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat}, author={Chandra R. Tate and Lyndsay V. Rhodes and H. Chris Segar and Jennifer L Driver and F. Nell Pounder and Matthew E. Burow and Bridgette M. Collins-Burow}, booktitle={Breast Cancer Research}, year={2012} }